The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
One in three people will be diagnosed with cancer in their lifetime. Providence works tirelessly in the areas of patient care, research, education, clinical trials, and cutting-edge treatments for cancer.
Our network of cancer specialists—research scientists; medical, surgical and radiation oncologists; advanced pathologists, diagnostic imaging experts; oncology nurses; physical therapists; nutritionists; support services; social workers; spiritual care providers and more—care for 40,000+ cancer patients each year, including over 7,400 breast cancer, 3,000 bronchus lung cancer, and 2,500 prostate cancer patients.
Leveraging this team of world-class physicians, scientists and medical specialists, Providence ensures patients have access to clinical trials and the most effective treatment options available, customized for them.
With your generous support, we will advance cancer research to find breakthrough treatments and provide the most advanced care possible.
Your generous gift gives makes clinical excellence possible and gives doctors access to the latest research, data, best-practice findings and reports, making quality health services available to cancer patients in every community we serve. Thank you for your support of this important work.
The Providence Cancer Institute of Oregon is one of only four locations worldwide recruiting patients with advanced solid tumors of any type that have relapsed or are unresponsive to treatment for a phase I dose-escalation study of IO-108 as a monotherapy and in combination with pembrolizumab, an immunotherapy.
Eric Tran, Ph.D., Assistant Member, Adoptive Cell Therapy Laboratory, at the Providence Cancer Institute’s Earle A. Chiles Research Institute, and his team are pioneering breakthroughs in cancer immunotherapy, a “global first” in tumor reduction efforts. The work infuses reprogrammed T-cells to target cancerous cells and remove them from the body. It shows that our immune system is capable of curing advanced cancer.
When Kathy Wilkes’ stage three pancreatic cancer didn’t respond to traditional treatment, she found an experimental immunotherapy treatment at the Providence Cancer Institute. After six months the tumors in her lungs shrunk by 72 percent.
At Oregon’s Providence Cancer Institute, researcher Eric Tran genetically engineered T cells to spot a mutant protein hidden inside tumor cells—and only there, not in healthy cells. In this novel experiment, a woman with advanced pancreatic cancer saw her tumors dramatically shrink after her own immune cells were turbocharged, highlighting a possible new way to someday treat a variety of cancers.
The $20 million gift, made shortly after his death in 2018, supports the creation of the Paul G. Allen Research Center at Providence Swedish.
Oncology is being transformed as a result of research that shows how the immune system can recognize and destroy cancer cells. Dr. Walter J. Urba shares how philanthropy fuels cancer research, clinical trials and cutting-edge laboratory equipment that lead to these lifesaving treatments.
